Accuray's (ARAY) Radixact Treatment Delivery Platform Receives FDA 510(k) Clearance

Go back to Accuray's (ARAY) Radixact Treatment Delivery Platform Receives FDA 510(k) Clearance

Accuray Receives 510(k) FDA Clearance for the Radixactâ„¢ Image-Guided Radiation Therapy Platform and Integrated Software

June 27, 2016 6:30 AM EDT

SUNNYVALE, Calif., June 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System. These next generation hardware and software solutions which, together, make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment.  The... More